Justin Smith1, Domenico Nastasi1, Reece Tso1, Venkat Vangaveti1, Bronia Renison2, Madhavi Chilkuri3. 1. College of Medicine and Dentistry, James Cook University, Townsville, Australia. 2. The Townsville Health Library, Australia. 3. College of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Radiation Oncology, The Townsville Hospital, Australia. Electronic address: madhavi.chilkuri@health.qld.gov.au.
Abstract
PURPOSE: To determine the effects of continued smoking in head and neck cancer (HNC) patients undergoing radiotherapy on overall survival (OS), locoregional control (LRC), quality of life (QoL) and acute and late toxicities. METHODS: Articles from January 1990 to August 14, 2018 were searched in PubMed, MEDLINE (Ovid), Embase, Scopus, The Cochrane Library, CINAHL and AUSThealth. Articles were included if majority of patients were treated with radiotherapy and smokers were defined as those who continued to smoke during or after radiotherapy. Data extraction and risk of bias assessment was performed by three independent co-authors using summary data of original studies. A meta-analysis using a random effects model was conducted for OS and LRC. In addition, a qualitative synthesis was performed for toxicities and quality of life as only a limited number of articles were available. RESULTS: The initial search identified 2217 studies, with 24 articles comprising 6332 patients eligible for inclusion. Analysis demonstrated that continued smoking was associated with approximately two times the risk of mortality (RR = 1.85, 95% CI 1.55-2.21, p < 0.0001, I2 = 43%) in HNC patients. Similarly, the risk of locoregional failure was more than two times greater in HNC patients who continued smoking (RR = 2.24, CI 1.42-3.52, p = 0.0005, I2 = 64%). The qualitative synthesis indicates that continued smoking may contribute to an elevated incidence of late but not acute toxicities. CONCLUSIONS: This review provides evidence that continued smoking is associated with a lower OS and LRC and a higher incidence of late toxicities. Therefore, clinicians should strongly encourage smoking cessation amongst all head and neck cancer patients.
PURPOSE: To determine the effects of continued smoking in head and neck cancer (HNC) patients undergoing radiotherapy on overall survival (OS), locoregional control (LRC), quality of life (QoL) and acute and late toxicities. METHODS: Articles from January 1990 to August 14, 2018 were searched in PubMed, MEDLINE (Ovid), Embase, Scopus, The Cochrane Library, CINAHL and AUSThealth. Articles were included if majority of patients were treated with radiotherapy and smokers were defined as those who continued to smoke during or after radiotherapy. Data extraction and risk of bias assessment was performed by three independent co-authors using summary data of original studies. A meta-analysis using a random effects model was conducted for OS and LRC. In addition, a qualitative synthesis was performed for toxicities and quality of life as only a limited number of articles were available. RESULTS: The initial search identified 2217 studies, with 24 articles comprising 6332 patients eligible for inclusion. Analysis demonstrated that continued smoking was associated with approximately two times the risk of mortality (RR = 1.85, 95% CI 1.55-2.21, p < 0.0001, I2 = 43%) in HNC patients. Similarly, the risk of locoregional failure was more than two times greater in HNC patients who continued smoking (RR = 2.24, CI 1.42-3.52, p = 0.0005, I2 = 64%). The qualitative synthesis indicates that continued smoking may contribute to an elevated incidence of late but not acute toxicities. CONCLUSIONS: This review provides evidence that continued smoking is associated with a lower OS and LRC and a higher incidence of late toxicities. Therefore, clinicians should strongly encourage smoking cessation amongst all head and neck cancerpatients.
Authors: Andrew F Brouwer; Kevin He; Steven B Chinn; Alison M Mondul; Christina H Chapman; Marc D Ryser; Mousumi Banerjee; Marisa C Eisenberg; Rafael Meza; Jeremy M G Taylor Journal: Cancer Date: 2020-09-05 Impact factor: 6.860
Authors: Saverio Caini; Marco Del Riccio; Virginia Vettori; Oriana D'Ecclesiis; Pierluigi Bonomo; Luca Giovanni Locatello; Viola Salvestrini; Oreste Gallo; Marta Tagliabue; Sara Raimondi; Calogero Saieva; Flavia Cozzolino; Benedetta Bendinelli; Sara Gandini Journal: Br J Cancer Date: 2022-08-23 Impact factor: 9.075
Authors: Dustin A Silverman; Chen Lin; Akina Tamaki; Sidharth V Puram; Ricardo L Carrau; Nolan B Seim; Antoine Eskander; James W Rocco; Matthew O Old; Stephen Y Kang Journal: Head Neck Date: 2020-04-30 Impact factor: 3.147
Authors: Brian O'Sullivan; Shao Hui Huang; Thomas Keane; Wei Xu; Jie Su; John Waldron; Patrick Gullane; Fei-Fei Liu; Padraig Warde; David Payne; Li Tong; Bernard Cummings Journal: Clin Transl Radiat Oncol Date: 2020-01-28
Authors: Patricia Fitzpatrick; Nancy Bhardwaj; Ailsa Lyons; Kirsten Doherty; Kate Frazer; Amanda McCann; Vikram Niranjan; Shiraz Syed; Patricia Fox Journal: Int J Environ Res Public Health Date: 2022-02-18 Impact factor: 3.390
Authors: Hesham Elhalawani; Abdallah S R Mohamed; Baher Elgohari; Timothy A Lin; Andrew G Sikora; Stephen Y Lai; Abdelrahman Abusaif; Jack Phan; William H Morrison; G Brandon Gunn; David I Rosenthal; Adam S Garden; Clifton D Fuller; Vlad C Sandulache Journal: BMC Cancer Date: 2020-09-23 Impact factor: 4.430